Navigation Links
Medical Researchers Say They Have Made a Breakthrough That Could Lead to a Potential Cure for AIDS
Date:9/1/2013

Auckland, NZ (PRWEB) September 01, 2013

Dr Richard Teague, spokesperson for Regenex Laboratories, says they have discovered how to use selected proteins within an ovine placenta extract base and combine it with peptides and signaling molecules designed to ‘wake up’ dormant stem cells in the body.

"Peptides are considered the future of medicine," he said. "And with this technology, using fractionated OVP in combination with peptides, we can provide an answer to HIV by reactivating the patient’s immune system."

"Up until now these products have only used in the controversial anti-ageing field, but now we have evidence that they actually do re-activate a person's stem cells. The stem cells are intelligent in that they seek out the area of most need in the body and repair it."

Dr Teague says the injectable cannot eradicate HIV from the body but it could potentially end the disease, as it provides a healthy immune system so patients can handle normal infections."

More than 33 million people have been diagnosed with HIV worldwide.

If clinical trials are successful, one initial 12 week course followed by a single dose every 3-4 months could be effective enough to replace the multiple therapies they currently need.

The key to the Immune Booster IM product is the filtering process which is used in the production process. The company has been able to achieve a filtration of less than 50,000 Dalton units, meaning the 5mg dose can be safely injected intramuscular, rather than having to be done intravenously.

"We have spent several years developing the production process and this is cutting edge technology now available to consumers worldwide."

"With HIV you have 2 options. You either have to eliminate the virus infection from the body, or you have to provide the body a mechanism by which it can naturally fight off simple diseases which to a HIV sufferer can be fatal. Immune Booster IM does that by activating dormant stem cells."

Dr Teague says that while the product is readily available now for anti ageing, and other conditions such as Rheumatoid arthritis and crones disease, the product is yet to undergo trials for HIV.

"This particular study is going to take some time, but so far every test that we have put this product through has passed with flying colors, and we have enough initial human tests results to know we have something special here," he said.

Successful clinical trials would present a rare bright spot in the ongoing battle against HIV. In August this year, U.S. trials for a potential AIDS vaccine were called off after the National Institute of Allergy and Infectious Diseases found the treatment — HVTN 505 —statistically ineffective compared to a placebo. (A cure differs from a vaccine in that the former works on people who have already contracted the virus.)

Immune Booster IM will be marketed as a cure since early trials indicate it has the ability to completely reverse the AIDS potency in the body, by boosting T-Cell counts and decreasing viral load. This comes about by the body itself fighting off the disease, after being re-activated by the Immune Booster IM.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11082049.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
3. CAM therapy combined with conventional medical care may improve treatment of lower back pain
4. Image share project gives patients and physicians anytime, anywhere access to medical images
5. Researchers determine vitamin D blood level for reducing major medical risks in older adults
6. Biomedical researchers receive Hartwell Foundation awards
7. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
8. Fitness in Middle Age Lowers Medical Costs Later: Study
9. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
10. Gene Tests May Not Drive Patients to More Medical Care
11. University studies and career expectations of medical students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: